Elucid Bioimaging, Inc. in Boston underwent an inspection by the Food and Drug Administration (FDA) on March 20, according to data available on the FDA’s website.
The inspection’s final report stated that Elucid Bioimaging, Inc. was advised to address operational management related to device compliance. No further action was needed in other areas.
The FDA conducts regular inspections at facilities nationwide to assess whether workplaces and their products comply with FDA laws and regulations intended to protect public health. Results of such inspections are shared with the public.
According to its website, the FDA serves as the government agency charged with overseeing the safety and quality of human and animal drugs, biologic products, medical devices and tobacco products.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
